These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20456401)

  • 21. Active tuberculosis in a psoriasis patient treated with tumor necrosis factor inhibitors despite an initial negative tuberculin skin test and no known risk factors.
    Gilbert KE; Manalo IF; Wu JJ
    Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting.
    Kardos M; Kimball AB
    J Am Acad Dermatol; 2012 Jan; 66(1):148-52. PubMed ID: 22177633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells co-producing Mycobacterium tuberculosis-specific type 1 cytokines for the diagnosis of latent tuberculosis.
    Nemeth J; Winkler HM; Karlhofer F; Selenko-Gebauer N; Graninger W; Winkler S
    Eur Cytokine Netw; 2010 Mar; 21(1):34-9. PubMed ID: 20146988
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients.
    Andrisani G; Armuzzi A; Papa A; Marzo M; Felice C; Pugliese D; De Vitis I; Rapaccini GL; Guidi L
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):21-5. PubMed ID: 23539386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of QuantiFERON-TB Gold test and tuberculin skin test for the identification of latent Mycobacterium tuberculosis infection in lupus patients.
    Yilmaz N; Zehra Aydin S; Inanc N; Karakurt S; Direskeneli H; Yavuz S
    Lupus; 2012 Apr; 21(5):491-5. PubMed ID: 22140142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How frequently do tuberculosis screening tests convert in inflammatory bowel disease patients on anti-tumour necrosis factor-alpha? A pilot study.
    Bermejo F; Algaba A; Chaparro M; Taxonera C; Garrido E; García-Arata I; Guerra I; Gisbert JP; Olivares D; de-la-Poza G; López-Sanromán A
    Dig Liver Dis; 2013 Sep; 45(9):733-7. PubMed ID: 23587496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of tuberculosis infection by interferon-gamma release assays in patients with psoriasis.
    Latorre I; Carrascosa JM; Vilavella M; Díaz J; Prat C; Domínguez J; Ferrándiz C
    J Infect; 2014 Dec; 69(6):600-6. PubMed ID: 25148944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.
    Helwig U; Müller M; Hedderich J; Schreiber S
    J Crohns Colitis; 2012 May; 6(4):419-24. PubMed ID: 22398067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
    Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
    J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
    Lee EB; Amin M; Man J; Egeberg A; Wu JJ
    J Dermatolog Treat; 2018 Nov; 29(7):671-675. PubMed ID: 29455561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests.
    Prignano F; Bartoloni A; Bartalesi F; Gori A; Ricceri F; Cavallo A; Attala L; Mantella A
    Int J Dermatol; 2014 Aug; 53(8):e372-4. PubMed ID: 24898978
    [No Abstract]   [Full Text] [Related]  

  • 32. The use of an interferon-gamma release assay to screen for pediatric latent tuberculosis infection in the eastern region of the Emirate of Abu Dhabi.
    Al Mekaini LA; Al Jabri ON; Narchi H; Kamal SM; Mabrook A; Al Kuwaiti MM; Sheek-Hussein MM; Souid AK; Alsuwaidi AR
    Int J Infect Dis; 2014 Jun; 23():4-7. PubMed ID: 24657274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.
    Singanayagam A; Manalan K; Sridhar S; Molyneaux PL; Connell DW; George PM; Kindelerer A; Seneviratne S; Lalvani A; Wickremasinghe M; Kon OM
    Thorax; 2013 Oct; 68(10):955-61. PubMed ID: 23976779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of immunosuppressive therapy on QuantiFERON and tuberculin skin test for screening of latent tuberculosis in patients with inflammatory bowel disease scheduled for anti-TNF therapy.
    Mantzaris GJ; Tsironikos D; Tzanetakou X; Grispou E; Karatzas P; Kalogeropoulos I; Papamichael K
    Scand J Gastroenterol; 2015; 50(12):1451-5. PubMed ID: 26139305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection.
    Chen YM; Chen HH; Lai KL; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2013 Apr; 52(4):697-704. PubMed ID: 23264552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Latent Tuberculosis Infection Screening and 2-Year Outcome in Antiretroviral-Naive HIV-Infected Patients in a Low-Prevalence Country.
    Bourgarit A; Baron G; Breton G; Tattevin P; Katlama C; Allavena C; Campa P; Ravaud P; Lortholary O; Carcelain G;
    Ann Am Thorac Soc; 2015 Aug; 12(8):1138-45. PubMed ID: 26213798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IFN-γ/TNF-α ratio in response to immuno proteomically identified human T-cell antigens of Mycobacterium tuberculosis - The most suitable surrogate biomarker for latent TB infection.
    Prabhavathi M; Pathakumari B; Raja A
    J Infect; 2015 Aug; 71(2):238-49. PubMed ID: 25936741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of replacing tuberculin skin test with ex vivo interferon γ release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy.
    Mariette X; Baron G; Tubach F; Lioté F; Combe B; Miceli-Richard C; Flipo RM; Goupille P; Allez M; Salmon D; Emilie D; Carcelain G; Ravaud P
    Ann Rheum Dis; 2012 Nov; 71(11):1783-90. PubMed ID: 22258485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?
    Soysal A; Toprak D; Koc M; Arikan H; Akoglu E; Bakir M
    Nephrol Dial Transplant; 2012 Apr; 27(4):1645-50. PubMed ID: 21931124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.